Tongue Cancer Completed Phase 1 Trials for Erlotinib (DB00530)

IndicationStatusPhase
DBCOND0029843 (Tongue Cancer)Completed1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00049283Erlotinib, Docetaxel, and Radiation Therapy in Treating Patients With Locally Advanced Head and Neck CancerTreatment
NCT00397384Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal CancerTreatment